Glaukos Co. (NYSE:GKOS) Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. decreased its position in shares of Glaukos Co. (NYSE:GKOS) by 5.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,503 shares of the medical instruments supplier’s stock after selling 3,200 shares during the quarter. Prudential Financial Inc.’s holdings in Glaukos were worth $8,322,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. IFP Advisors Inc acquired a new stake in Glaukos during the fourth quarter valued at $43,000. Asset Planning Inc purchased a new position in shares of Glaukos in the 4th quarter valued at about $90,000. Picton Mahoney Asset Management acquired a new position in Glaukos in the 4th quarter worth about $125,000. SBI Securities Co. Ltd. purchased a new position in Glaukos during the fourth quarter worth approximately $153,000. Finally, Smartleaf Asset Management LLC grew its holdings in Glaukos by 275.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock valued at $164,000 after purchasing an additional 807 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Stock Performance

NYSE:GKOS opened at $101.97 on Friday. The company’s 50-day moving average is $130.52 and its two-hundred day moving average is $135.71. Glaukos Co. has a 1-year low of $88.16 and a 1-year high of $163.71. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The firm has a market capitalization of $5.77 billion, a price-to-earnings ratio of -35.53 and a beta of 0.99.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $105.50 million during the quarter, compared to analysts’ expectations of $100.72 million. Analysts forecast that Glaukos Co. will post -1.08 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on GKOS. Piper Sandler reissued an “overweight” rating and issued a $180.00 price target (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. Truist Financial upped their price target on shares of Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Stifel Nicolaus boosted their price objective on Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, December 31st. Stephens raised Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Wells Fargo & Company increased their price objective on Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $163.25.

Insider Buying and Selling

In related news, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the transaction, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company’s stock.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.